Literature DB >> 25605578

Abridged adapter primers increase the target scope of Hi-Plex.

Tú Nguyen-Dumont1, Fleur Hammet1, Maryam Mahmoodi1, Bernard J Pope2, Graham G Giles3, John L Hopper4, Melissa C Southey1, Daniel J Park1.   

Abstract

Previously, we reported Hi-Plex, an amplicon-based method for targeted massively parallel sequencing capable of generating 60 amplicons simultaneously. In further experiments, however, we found our approach did not scale to higher amplicon numbers. Here, we report a modification to the original Hi-Plex protocol that includes the use of abridged adapter oligonucleotides as universal primers (bridge primers) in the initial PCR mixture. Full-length adapter primers (indexing primers) are included only during latter stages of thermal cycling with concomitant application of elevated annealing temperatures. Using this approach, we demonstrate the application of Hi-Plex across a broad range of amplicon numbers (16-plex, 62-plex, 250-plex, and 1003-plex) while preserving the low amount (25 ng) of input DNA required.

Keywords:  Hi-Plex; genetic screening; massively parallel sequencing; mutation screening; next-generation sequencing; targeted sequencing

Mesh:

Substances:

Year:  2015        PMID: 25605578     DOI: 10.2144/000114247

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  3 in total

1.  Mutation screening of ACKR3 and COPS8 in kidney cancer cases from the CONFIRM study.

Authors:  Maryam Mahmoodi; Tu Nguyen-Dumont; Fleur Hammet; Bernard J Pope; Daniel J Park; Melissa C Southey; John M Darlow; Fiona Bruinsma; Ingrid Winship
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

2.  UNDR ROVER - a fast and accurate variant caller for targeted DNA sequencing.

Authors:  Daniel J Park; Roger Li; Edmund Lau; Peter Georgeson; Tú Nguyen-Dumont; Bernard J Pope
Journal:  BMC Bioinformatics       Date:  2016-04-16       Impact factor: 3.169

3.  Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations?

Authors:  Tú Nguyen-Dumont; Zhi L Teo; Fleur Hammet; Alexis Roberge; Maryam Mahmoodi; Helen Tsimiklis; Daniel J Park; Bernard J Pope; Andrew Lonie; Miroslav K Kapuscinski; Khalid Mahmood; David E Goldgar; Graham G Giles; Ingrid Winship; John L Hopper; Melissa C Southey
Journal:  BMC Cancer       Date:  2018-02-08       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.